Syndax Pharmaceuticals Inc. has announced the publication of data from the BEAT AML trial in the Journal of Clinical Oncology. This trial evaluated the combination of revumenib with venetoclax and azacitidine in newly diagnosed mutant NPM1 (mNPM1) and KMT2A-rearranged (KMT2Ar) acute myeloid leukemia $(AML.AU)$ patients. The results were simultaneously presented at the 30th European Hematology Association Annual Congress in Milan, Italy, held from June 12-15, 2025, and virtually. Revumenib was generally well-tolerated and showed promising clinical activity, with a 67% complete response rate, 88% overall response rate, and 100% MRD negativity among responders. Enrollment for the pivotal Phase 3 EVOLVE-2 trial is currently underway, focusing on newly diagnosed mNPM1 AML patients unfit for intensive chemotherapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.